GRI Bio Completes Enrollment In Phase 2A Study Of GRI-0621 For The Treatment Of Idiopathic Pulmonary Fibrosis (“IPF”)
ReutersJul 1, 2025 12:54 PM
July 1 (Reuters) - GRI Bio Inc GRI.O:
GRI BIO COMPLETES ENROLLMENT IN PHASE 2A STUDY OF GRI-0621 FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (“IPF”)
GRI BIO INC - TOPLINE RESULTS FROM PHASE 2A STUDY EXPECTED IN Q3 2025
GRI BIO INC - GRI-0621 DEMONSTRATED SAFE AND WELL-TOLERATED IN INTERIM SAFETY RESULTS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Warsh’s Fed Era Signals a Death Knell for QE, Jolting the $30 Trillion Treasury Market
With Warsh’s nomination, his past proposals for governing the Federal Reserve are being brought to the forefront. A central issue is the formulation of a new "1951 Accord" to restructure the relationship between the Fed and the Treasury. Analysts suggest such a move could impact the $30 trillion TreTradingKey
13 hours ago
Will TRON Reach $10? TRX Price Prediction 2026 and Canary Staked ETF Update
Explore TRON's 2026 outlook: Will TRX reach $10? Get the latest on the Canary Staked ETF SEC status, Justin Sun's strategy, and TRX price predictions through 2032.TradingKey
14 hours ago
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.TradingKey
Fri, Feb 6
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
